In the current study, we showed that inhibition of TH by continuous low-dose α-MT administration initiated at the early stage was able to prevent LRRK2 G2019S mutation-induced DA neurodegeneration in our PD models. This evidence concerns the gene LRRK2 and Parkinson disease.